JNJ-54175446 is a potent and selective P2X7 Receptor Antagonist. JNJ-54175446 is potent, stable in liver microsomes and has an acceptable protein binding profile. JNJ-54175446 is highly permeable and has no evidence of efflux as measured by a Caco-2 cell line. JNJ-54175446 efficiently binds to recombinant rat and human P2X7 and to native tissues in both human and rat. JNJ-54175446 also inhibited P2X7 activity in human, rat, dog, mouse, and macaque Ca2+ flux assays and inhibited IL1-β release in human peripheral blood monocytes (pIC50 of 7.7 ± 0.1) and in human whole blood (pIC50 of 8.1 ± 0.1).
For research use only. We do not sell to patients.
Name | JNJ-54175446 |
---|---|
Iupac Chemical Name | (R)-(2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyrimidin-2-yl)-4-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl)methanone |
Molecular Formula | C18H13ClF4N6O |
Molecular Weight | 440.78 |
Smile | ClC1=C(C(F)(F)F)C=CC=C1C(N(CC2)[C@H](C)C(N=N3)=C2N3C4=NC=C(C=N4)F)=O |
InChiKey | CWFVVQFVGMFTBD-SECBINFHSA-N |
InChi | InChI=1S/C18H13ClF4N6O/c1-9-15-13(29(27-26-15)17-24-7-10(20)8-25-17)5-6-28(9)16(30)11-3-2-4-12(14(11)19)18(21,22)23/h2-4,7-9H,5-6H2,1H3/t9-/m1/s1 |
CAS Number | 1627902-21-9 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% Min. |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1: Letavic MA, Savall BM, Allison BD, Aliusio L, Andrés JI, De Angelis M, Ao H, Beauchamp DA, Bonaventure P, Bryant S, Carruthers NI, Ceusters M, Coe KJ, Dvorak CA, Fraser I, Gelin CF, Koudriakova T, Liang J, Lord B, Lovenberg TW, Otieno M, Schoetens F, Swanson DM, Wang Q, Wickenden AD, Bhattacharya A. 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. J Med Chem. 2017 May 11. doi: 10.1021/acs.jmedchem.7b00408. [Epub ahead of print] PubMed PMID: 28493698.